Bone Marrow Transplantation News

Approximately one in 12 patients with a common primary tumor were diagnosed with a second primary malignancy between 1992 and 2008, according to results of a SEER analysis.

Hematopoietic stem cell transplantation preceded by induction therapy with bortezomib and dexamethasone plus doxorubicin or cyclophosphamide improved PFS and induced high response rates among patients with primary plasma cell leukemia, according to the results of a phase 2 study.

Delirium occurs frequently but appears underdiagnosed in patients with advanced cancer who presented in the ED, according to the results of a randomized observational study.

Richard J. O’Reilly, MD, of Memorial Sloan Kettering Cancer Center has been named the inaugural recipient of The Society of Memorial Sloan Kettering Prize.

ASH selected 15 medical students and 15 residents to receive the 2016 ASH HONORS Award.

ASH and the European Hematology Association selected 20 early-career hematologists to participate in the 2016 Translational Research Training in Hematology joint program.

Donor Epstein–Barr virus donor and recipient status significantly influenced risk for acute and chronic graft-versus-host disease among patients with leukemia undergoing allogeneic hematopoietic stem cell transplantation, according to study results from the European Society for Blood and Marrow Transplantation.

Dean Lee, MD, PhD, has been appointed director of the cellular therapy and cancer immunotherapy program for Nationwide Children’s Hospital’s division of hematology/oncology/bone marrow transplantation and its Center for Childhood Cancer and Blood Diseases.

Ipilimumab induced complete responses among patients with hematologic malignancies who relapsed following allogeneic hematopoietic stem cell transplantation, according to the results of a study published in The New England Journal of Medicine.

Memorial Sloan Kettering Cancer Center launched a new initiative designed to help teens and young adults with cancer.